These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26306819)

  • 21. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
    Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
    J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
    Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Hough D; Mathews M
    Int Clin Psychopharmacol; 2017 Nov; 32(6):329-336. PubMed ID: 28806194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort.
    Martínez-Andrés JA; García-Carmona JA
    Int Clin Psychopharmacol; 2020 May; 35(3):163-169. PubMed ID: 31851035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
    Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
    Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
    Lai JK; Margolese HC
    Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
    [No Abstract]   [Full Text] [Related]  

  • 27. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
    [No Abstract]   [Full Text] [Related]  

  • 28. Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.
    Samtani MN; Nandy P; Ravenstijn P; Remmerie B; Vermeulen A; Russu A; D'hoore P; Baum EZ; Savitz A; Gopal S; Hough D
    Br J Clin Pharmacol; 2016 Nov; 82(5):1364-1370. PubMed ID: 27333588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate.
    Kern Sliwa J; Savitz A; Nuamah I; Mathews M; Gopal S; Elefant E; Najarian D; Alphs L
    Perspect Psychiatr Care; 2018 Oct; 54(4):530-538. PubMed ID: 29446084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
    Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
    J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections.
    Debaveye S; De Smedt D; Heirman B; Kavanagh S; Dewulf J
    BMC Health Serv Res; 2019 Jun; 19(1):393. PubMed ID: 31217000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly.
    Geerts H; Spiros A; Roberts P; Alphs L
    Schizophr Res; 2018 Jul; 197():261-268. PubMed ID: 29395607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
    Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
    Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults.
    Cirnigliaro G; Battini V; Castiglioni M; Renne M; Mosini G; Cheli S; Carnovale C; Dell'Osso B
    Expert Rev Neurother; 2024 Apr; 24(4):325-332. PubMed ID: 38445396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting.
    Cirnigliaro G; Battini V; Cafaro R; Mosini G; Vanzetto S; Prodi T; Macellaro M; Leuzzi R; Conti D; Carnovale C; Dell'Osso B
    Expert Rev Neurother; 2023; 23(11):1031-1039. PubMed ID: 37750003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study.
    Wallman P; Clark I; Taylor D
    J Psychiatr Res; 2022 Apr; 148():131-136. PubMed ID: 35123325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.
    Mathews M; Nuamah I; Savitz AJ; Hough DW; Najarian D; Kim E; Gopal S
    Neuropsychiatr Dis Treat; 2018; 14():2807-2816. PubMed ID: 30498351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once-monthly paliperidone palmitate long-acting injection in an elderly patient with schizophrenia.
    Rama Raj P; Lewis M; Macfarlane S
    BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26311017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
    Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
    J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.